Small Business Boom Is Quietly Benefiting These Dividend Stocks
Ignore the vanilla mainstream media. Small business mojo is gaining steam. Main Street getting its groove back will directly benefit these two dividend stocks.
The NFIB Small Business Optimism Index washed out in April alongside the stock market. Despair hit desperation levels not seen since December 2012. But the malaise has quickly given way to positivity.
Small biz sentiment has increased for two straight months and counting. Why the turnaround? Two letters: AI.
Shanell Camp, owner of Shaded by Shanell (an up-and-coming beauty brand) explained her excitement to me about ChatGPT, her 'go to' resource for brainstorming, marketing help and more.
'I even named him Ace. We are in a full-blown work relationship. That is my best friend, my assistant, my email writer—everything. I use ChatGPT for a lot of stuff in the business and it's very, very helpful.'
Shanell and Ace are a dynamic duo. Together they are successfully competing with giant beauty brands that have much deeper pockets.
My friend and co-author Tom Jacobs, founder of Sark, a mobile word game, is similarly smitten with GPT. 'Brett, it's the best marketer I've ever met,' Tom raved to me. 'It's like having an entire marketing department at my fingertips.'
In years past, small business owners like Shanell and Tom would have had to hire expensive humans who would deliver a fraction of the output of ChatGPT. These are salad days for owners who are embracing AI tools, and who can blame them for being so excited?
When small business owners are feeling good, they think big—and expand.
That expansion still requires capital. Maybe not as much for hiring humans, but for scaling, marketing, inventory and even ChatGPT Pro!
Where to get the cash? For years, small businesses have bypassed the difficult-to-borrow-from banks and raised capital from business development companies (BDCs).
2 Dividend Stocks To Own Now
So when small business cooks, BDC lending profits sizzle. And we have two menu favorites here at Contrarian Outlook. One is the biggest, steadiest lender; the other is the steadiest dividend grower. Let's talk about both top-shelf favorites: Ares Capital (ARCC) and Main Street Capital (MAIN).
ARCC is the biggest BDC by far, with over $22 billion in assets. This scale brings it a steady stream of deal flow, which then helps management dictate favorable loan terms.
No wonder we lovingly call Ares our 'BDC Bully' because its size lets it seize market share when others panic. That playbook paid off in 2020, and it's working again today.
Yup, the private credit market is still growing, and ARCC is aggressively writing new loans at attractive yields. Last quarter, ARCC generated net investment income (NII) of $0.50 per share, covering its $0.48 quarterly dividend.
Better still, ARCC is picky. Loans where borrowers aren't paying are just 1.5% of the portfolio. That's a healthy number for a lender in this 'middle-market' credit space (companies with sales between $10 million and $1 billion)—industry average is 2.6%.
ARCC Dividend
ARCC yields 8.8%, and the payout is supported by current income. That's a rare combo of yield and quality in this market. We'll keep collecting from this bully.
MAIN, our other favorite, is never cheap. It always trades at a premium to its book value in a world where many lesser BDCs trade at discounts. Most of those stocks are cheap for a reason, however. MAIN has absolutely manhandled the industry benchmark VanEck BDC Income ETF (BIZD) since the latter's inception:
MAIN Outperforms
MAIN invests by lending money and providing equity capital (think of it as both lender and part-owner) to smaller, growing companies. These are typically private businesses that aren't huge but big enough to be stable and profitable.
Specifically, MAIN looks for companies between $25 million and $500 million in annual revenues, with profits (EBITDA, a good measure of core earnings) ranging from about $7.5 million to $50 million. Think of a thriving regional manufacturer, a specialty healthcare provider, or a niche business-services firm—companies that are successful but still have plenty of runway for growth.
MAIN also provides straightforward loans to slightly larger 'middle-market' firms and even manages assets and offers advisory services, rounding out its approach to creating income from solid, Main Street businesses (sorry, couldn't resist!).
Its portfolio is impressively diverse. Right now, MAIN holds investments across 190 different companies. What's reassuring is that its largest holding makes up just 3.8% of the portfolio—so no single company can overly sway MAIN's performance. (In fact, most investments are less than 1%!) Even better, these holdings span dozens of industries, and MAIN doesn't let any one industry dominate (none tops 10% of its investments). It's exactly the kind of broad diversification that helps manage potential portfolio heartburn.
This lender and part-owner often increases its monthly dividend and quarterly 'supplemental' payout. In 2009, MAIN paid total dividends of $1.50 per share. Fast forward to last year and the company distributed $4.11 per share—$2.91 in regularly monthly dividends and $1.20 in supplemental dividends—good for a 174% increase in 15 years.
MAIN currently pays a generous 7.2%, with the majority (about 5.5%) delivered through dependable monthly payments. Even nicer are the regular 'supplemental' dividends it dishes out quarterly—think of these as extra rewards for shareholders, per this pretty payout picture:
MAIN Dividend
We have two top-shelf picks here at Contrarian Outlook—one is the biggest and most reliable lender, the other the steadiest dividend grower. Why choose? Let's own both BDC GOATs.
MAIN and ARCC yield a blended 8.1% today. And based on Main Street's mood, those dividends aren't just secure—they're likely to grow. I think Ace would approve—as would our small business owner friends.
Brett Owens is Chief Investment Strategist for Contrarian Outlook. For more great income ideas, get your free copy his latest special report: How to Live off Huge Monthly Dividends (up to 8.7%) — Practically Forever.
Disclosure: none
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
27 minutes ago
- Yahoo
Why Nektar Therapeutics Stock Dived by 3% Today
The company announced it closed its latest capital-raising effort. This took the form of a nearly 5-million strong, secondary share issue. 10 stocks we like better than Nektar Therapeutics › Nektar Therapeutics (NASDAQ: NKTR) saw its stock price erode on Thursday, following the company's closing of a secondary stock issue. Investors gave the company a thumbs-down on the news by selling out of its shares, leaving it with a 3% loss at the close of trading. Meanwhile, the benchmark S&P 500 index ticked up on the day, rising by 0.8%. Just after market hours on Wednesday, Nektar announced that it completed that new share flotation. The clinical-stage biotech sold slightly more than 4.89 million shares of its common stock. Within that number were 638,298 that were sold to the underwriters of the issue. Collectively, those entities fully exercised their option to buy Nektar stock. The gross proceeds of the issue, which was priced at $23.50 per share, amounted to roughly $115 million. Nektar wrote that it aims to deploy the new funds for "general corporate purposes," which might include drug development and manufacturing, and research and development activities. As often happens with secondary share flotations, particularly in the frequently cash-hungry biotech space, this one is notably dilutive to existing shareholders. Prior to this issue, Nektar had slightly more than 12.4 million common shares outstanding. So that nearly 5 million share-count addition is going to make a difference -- and not in a positive way. At least the money is being raised by a business with potential. Relatively speaking, Nektar has quite a few pipeline projects in development. Its leading one, rezpegaldesleukin, recently tested quite well for treating moderate-to-severe atopic dermatitis, a skin disorder. That said, the new shares are weighing on the company, and investors are probably worried that more equity offerings are coming, hence more dilution. While a company's share count shouldn't be the only consideration when evaluating a stock, it does matter, and this latest one from Nektar has sparked concern. Before you buy stock in Nektar Therapeutics, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Nektar Therapeutics wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $692,914!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $963,866!* Now, it's worth noting Stock Advisor's total average return is 1,049% — a market-crushing outperformance compared to 179% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 30, 2025 Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. Why Nektar Therapeutics Stock Dived by 3% Today was originally published by The Motley Fool Sign in to access your portfolio
Yahoo
30 minutes ago
- Yahoo
Remote Pharmacy Releases 2025 Availability Update on GLP-1 Weight Loss Solutions and Consumer Interest in Semaglutide & Tirzepatide
In this 2025 availability update, Remote Pharmacy highlights the expanded access to non-branded GLP-1-based weight management options, including semaglutide and tirzepatide compounds. The release explores the evolving role of compounded therapeutics, shifts in consumer behavior toward remote prescribing, and how new formulations align with the growing interest in safe, physician-directed care for weight management. Bowling Green, July 03, 2025 (GLOBE NEWSWIRE) -- Section 1 – Introduction In 2025, the discourse surrounding prescription weight loss treatments is gaining momentum, fueled by increasing public awareness of GLP-1 receptor agonists, such as semaglutide and tirzepatide. Developed initially as antidiabetic agents, these medications are now at the forefront of interest in physician-monitored, non-surgical weight management protocols. The surge in online traffic related to terms like 'GLP-1 weight loss treatment,' 'semaglutide injections for weight loss,' and 'tirzepatide therapy' is a clear sign of a cultural shift towards science-based, regulated solutions over unverified or fad-driven alternatives. This evolution is taking place alongside a broader redefinition of healthcare delivery itself. As more consumers seek accessible, discreet, and flexible care models, telehealth platforms like Remote Pharmacy have become essential vehicles for accessing physician-guided prescription options from the comfort of their own homes, particularly in areas such as metabolic health, where continuity and personalization are crucial. Remote Pharmacy, as a telehealth platform, facilitates the connection between patients and U.S.-licensed physicians, ensuring safe and convenient access to prescription-based weight management options. Today's health-conscious consumer is no longer swayed solely by brand name recognition or conventional in-office protocols. Instead, there is a growing interest in non-branded GLP-1 compounds, compounded semaglutide with vitamin B12, and other clinically reviewed alternatives available through compliant pharmacy networks. This shift in consumer behavior reflects a broader desire for affordability, customization, and most importantly, licensed oversight, rather than just rapid results or commercial hype. As the weight management segment continues to evolve, individuals are increasingly seeking information-driven, regulated access to therapies that align with their long-term lifestyle goals. Remote Pharmacy's platform, which delivers professional review, pharmacist fulfillment, and secure, HIPAA-compliant infrastructure, is instrumental in shaping the future of prescription-based weight management. It meets modern expectations of care, offering a unique blend of convenience, safety, and personalization. Section 2 – Product/Company Update Remote Pharmacy announces continued nationwide availability of its compounded GLP-1 formulations, including semaglutide and tirzepatide-based treatments, for eligible adults pursuing physician-directed weight management. The platform provides 100% virtual consultations, with prescriptions evaluated and dispensed by U.S.-licensed healthcare professionals through independent third-party medical groups and pharmacies. For informational access to physician-reviewed compounded GLP-1 treatment pathways, visit Patients may begin the intake process through a secure digital health questionnaire, reviewed by an independent medical provider. Instead, it offers a digital platform that enables individuals to access healthcare consultations and prescription fulfillment via licensed providers. All medical decisions and prescriptions are managed exclusively by third-party providers. Treatments are tailored to individual medical history, intake forms, and professional review. Doses are determined case-by-case — without tiered pricing or promotional variance — and may include compounded semaglutide with vitamin B12. Solutions are sourced from 503A-certified U.S. pharmacies and shipped discreetly to approved patients within 3–5 business days. Remote Pharmacy's offerings include multiple GLP-1 options, such as: Compounded Semaglutide injections Tirzepatide in dissolvable or oral formats Non-branded GLP-1 alternatives Each option is reviewed through a secure medical intake form and physician consultation, with no video calls required. All services are conducted in compliance with HIPAA privacy protocols and applicable telehealth regulations. Section 3 – Consumer Trend Overview Increased search interest in 'prescription weight loss,' 'GLP-1 medication for weight loss,' and 'semaglutide vs tirzepatide' reflects a changing consumer mindset. Rather than pursuing rapid or unregulated solutions, more individuals are seeking medical oversight, scientific transparency, and safe pathways to long-term metabolic support. Recent data suggests that U.S. adults are becoming more familiar with terms like 'GLP-1 agonist,' 'non-branded weight loss medication,' and 'compounded semaglutide,' signaling both awareness and demand. Online conversations have also shifted in tone — away from one-size-fits-all products and toward medically supervised approaches that offer privacy, customization, and consistency. This growing awareness coincides with a broader preference for digital-first health models. Consumers increasingly value asynchronous consultations, flexible intake processes, and delivery options that do not require pharmacy pickups or clinic visits. As part of that evolution, patients are actively comparing GLP-1-based options based on ingredient profile, route of administration, and physician access — not brand loyalty or promotional claims. Platforms offering a range of prescription-based GLP-1 treatments, such as semaglutide injections or oral tirzepatide, are gaining visibility among adults seeking solutions that feel medically grounded yet logistically simple. Search behavior shows a rise in queries for 'telehealth weight loss prescriptions,' 'GLP-1 compounded injections,' and 'custom weight loss plan with doctor review,' indicating demand for precision over generalization. Remote Pharmacy's infrastructure — built to support U.S.-licensed prescribers, pharmacy fulfillment, and HIPAA-compliant access — reflects the priorities of this consumer base. For informational access to compounded GLP-1 treatment pathways, visit Learn more about how Remote Pharmacy facilitates HIPAA-compliant access to GLP-1 compounds prescribed by licensed providers. Individuals interested in physician-directed weight management options can review eligibility via the Remote Pharmacy patient portal. The platform offers informational access without marketing pressure and provides a structure that places clinical review at the center of the weight loss conversation. Section 4 – Ingredient/Technology Spotlight Semaglutide and tirzepatide remain the most searched GLP-1-related compounds in 2025, as both have gained prominence in the context of non-branded, physician-prescribed weight management protocols. Each compound offers a distinct pharmacological profile and delivery pathway, with compounded options tailored by licensed prescribers based on an individual's medical history and treatment eligibility. Semaglutide is frequently cited in clinical literature for its role in regulating blood glucose levels and modulating satiety signals. In a compounded format, it may be paired with vitamin B12 for supportive wellness alignment. Vitamin B12, while not a therapeutic agent for weight management, is often included in wellness-focused regimens due to its role in energy metabolism and its support for overall nutrient balance, which can be beneficial in a weight management program. Tirzepatide is a dual GLP-1 and GIP receptor agonist, discussed in recent studies for its role in regulating multiple metabolic pathways. Compounded tirzepatide is available in non-injection formats, such as oral drops and dissolvable tablets, broadening access for individuals seeking alternatives to injectable protocols. This non-branded availability is subject to regulatory compounding oversight and individual prescription review. Remote Pharmacy's affiliated providers may prescribe compounded versions of these agents after reviewing the patient's submitted intake and determining suitability. All ingredients are compounded in 503A-certified pharmacies and dispensed in accordance with U.S. pharmacy laws. No weight loss outcomes are implied or guaranteed. The use of semaglutide, tirzepatide, or B12 is guided solely by licensed medical discretion and the individual's clinical profile. These formulations are not substitutes for clinical treatment of obesity or metabolic disease and are intended for eligible adults within a physician-directed care model. Section 5 – User Journey and Market Tone Public discussions around GLP-1 weight management increasingly focus on the patient journey — from eligibility screening to virtual prescribing and pharmacy coordination. Consumers are gravitating toward models that offer simplicity, discretion, and clinical legitimacy, particularly when exploring treatments like compounded semaglutide or tirzepatide under the guidance of a medical professional. Across forums and healthcare threads, prospective patients frequently express interest in secure, asynchronous platforms that enable them to initiate care at their convenience. As video visits are not required, many find value in the ability to complete a private intake form and receive prescription approval after physician review, especially when compared to in-office consultations that may feel rushed or limited in scope. Remote Pharmacy's technology-enabled model reflects this evolving preference. Individuals who qualify are supported by licensed third-party providers who manage all medical determinations, including treatment selection and dosing. A secure patient portal offers real-time access to prescription updates, order history, and support options. This structure reinforces patient confidence without exerting promotional influence, thereby placing the decision-making authority in the hands of licensed professionals. Many adults exploring GLP-1 prescription options report prioritizing ease of access, pharmacy reliability, and compliance with U.S. telehealth regulations. There is growing rejection of platforms that rely on promotional tactics, and increased demand for those that deliver transparent terms, fixed pricing, and optionality in format, such as oral tirzepatide or weekly compounded semaglutide injections. Rather than framing the journey as product-first, patient narratives increasingly reflect a process-focused mindset: one that values accuracy, physician engagement, and the ability to control treatment pace without pressure. In this context, Remote Pharmacy's offering is experienced not as a sales mechanism, but as a compliant access point for individualized care through a licensed provider network. Section 6 – Availability and Transparency Remote Pharmacy's weight loss solutions are available to eligible adults located within states where prescribing services are legally offered through the platform's independent clinical partners. All prescriptions require prior approval from a licensed physician and are evaluated based on submitted medical intake data. Access to compounded GLP-1 treatments, including semaglutide and tirzepatide, is subject to individual suitability and the discretion of third-party providers. Remote Pharmacy does not offer medical advice or diagnostic services. Instead, it facilitates secure, HIPAA-compliant access to licensed prescribers and 503A-certified U.S. pharmacies that independently manage patient evaluations and prescription fulfillment. Remote Pharmacy does not make medical decisions and is not influenced by its administrative role on the platform. Product availability, including format (injectable, dissolvable, or oral), is determined solely by the prescribing provider and may vary by location, compound stability, or the compounding pharmacy's capacity. Delivery times are typically 3–5 business days after approval and fulfillment, but may vary depending on pharmacy operations and shipping logistics. The information provided on Remote Pharmacy's website and intake portals is intended for general awareness only. No therapeutic outcomes are implied or guaranteed. Individuals should consult a qualified healthcare professional to determine the appropriateness of any treatment. Prescription access through Remote Pharmacy aligns with current U.S. telehealth regulations and is designed to facilitate informational engagement with independently licensed providers. Section 7 – Industry Context and Final Observations The growth of digital healthcare models has transformed how consumers engage with prescription therapies, particularly in areas such as weight management and metabolic wellness. As interest in GLP-1 receptor agonists expands, patients are increasingly drawn to prescription platforms that prioritize accessibility, provider discretion, and compound integrity, rather than promotional campaigns or tiered pricing. The rise of compounded GLP-1 formulations, including semaglutide and tirzepatide, signals a notable shift in the healthcare landscape. Once limited to specialty settings, compounded medications are now entering mainstream demand as regulated, physician-directed alternatives. For many individuals, these formulations offer options that align with personal health goals and logistical needs, especially when dispensed through 503A-certified U.S. pharmacies with provider oversight. Telehealth is no longer viewed as a temporary solution, but rather as a standard pathway for clinical engagement. From asynchronous consultations to digital refill management, the patient experience has moved beyond location-bound models. Today's platforms must offer more than convenience — they must demonstrate compliance, transparency, and adaptability to individual needs. Remote Pharmacy's technology-enabled framework reflects these new expectations. By separating its administrative platform from the clinical and pharmaceutical responsibilities of third-party partners, it maintains a neutral stance while enabling lawful prescription access. This model fosters consumer trust while avoiding the common pitfalls of unregulated online marketplaces and exaggerated marketing claims. As the industry continues to evolve, regulated platforms offering secure access to licensed prescribers and independently dispensed, non-branded medications are likely to define the future of weight-related telehealth. For a closer look at how digital pharmacy infrastructure is evolving, visit Section 8 – Public Commentary Theme Summary Public discussions around GLP-1 medications and physician-directed weight loss care have grown more nuanced in 2025. A review of online discourse, forum threads, and social media commentary reveals consistent themes, with interest and caution often expressed in parallel. A recurring point of interest involves the distinction between branded medications and compounded alternatives. Some individuals have noted curiosity about whether non-branded formulations offer greater flexibility, mainly when prescribed by licensed providers and dispensed through accredited compounding pharmacies. Others have expressed appreciation for asynchronous intake methods that reduce the barriers to access, while still preserving professional oversight. Concerns about over-marketed platforms and variable pricing models are also frequently raised. Public commentary often reflects a desire for fixed-cost structures, transparent eligibility requirements, and clearer communication from providers. In this context, services that avoid tiered plans, aggressive promotions, or comparisons to brand-name drugs resonate with individuals seeking a clinical, unbiased experience. There is also growing interest in format diversity. Some consumers prefer injectables prescribed by a physician, while others opt for oral or dissolvable delivery forms, particularly for their potential alignment with daily routines. While discussions often cite motivation or lifestyle fit, users typically acknowledge that outcomes vary and that consistency, rather than speed, is the primary focus. Importantly, commentary acknowledges that access to compounded GLP-1 does not guarantee weight loss or clinical transformation. Individuals appear increasingly aware of the role physician discretion plays in determining suitability, and are open about the need for ongoing communication with providers. This public tone suggests that consumers are approaching compounded GLP-1 treatments not as quick solutions, but as part of an informed, regulated health decision that balances access with accountability. About Remote Pharmacy Remote Pharmacy is a U.S.-based technology platform that enables individuals to access physician-reviewed, pharmacy-dispensed treatments through affiliated third-party providers. The company does not practice medicine or dispense pharmaceuticals; instead, it facilitates access to virtual healthcare in compliance with applicable laws. Its platform prioritizes discretion, HIPAA compliance, and user privacy, with no marketing-driven pricing or usage claims. Remote Pharmacy does not provide diagnostic or disease-treatment services; its offerings are for informational use only, in the context of wellness and lifestyle support. Contact: Remote Pharmacy Email: support@ Website: CONTACT: Email: support@ Website: in to access your portfolio
Yahoo
30 minutes ago
- Yahoo
Offering student loan payment assistance a ‘no brainer,' benefits manager says
This story was originally published on HR Dive. To receive daily news and insights, subscribe to our free daily HR Dive newsletter. SAN DIEGO — Applied Materials' student loan repayment program for employees reaped such rewards that the company more than doubled its annual contribution after the first year, Tes Fernandez, director of U.S. benefits for the company said Monday during a panel discussion at SHRM 2025. In year one, the manufacturing company contributed $2,000 per employee in direct repayment of workers' student loans. In the years that have followed, Applied Materials now pays out $4,800 per employee and uses the benefit as both a way to support generally newer hires, recent graduates and some underrepresented groups and as a recruiting tool. 'They had to go up to the CFO and ask for extra millions of dollars to add this benefit. A year later, they more than doubled the benefit amount, not because the CFO got generous, but because they were seeing the results of the benefits,' Chris Rinko, VP and student debt and health and wellness benefits administration account executive at Fidelity Investments, said during the panel, which he moderated. When it comes to student loan debt assistance, employers have two choices, Rinko explained. They can either provide a direct payment to student loan servicers to help pay down employees' loans, or they can elect to offer matching contributions in the 401(k) plans of workers who demonstrate they are making student loan payments. The direct payment method can be targeted to only apply to certain groups — those who earn less or those in a specific job, for example — and can have a set end date, Rinko said, while matching contributions are tied to a company's overall 401(k) plan offering and can't exclude any workers. Tracey Gannon, a senior benefits manager at eBay, said it was 'kind of a no-brainer' for the e-commerce company to offer matching funds after the passage of the SECURE 2.0 Act. The law gave employers the ability to match employee contributions to certain student loan payments. 'We felt that this was just such an easy first step,' Gannon said. The company already budgets for all employees to get the full matching contribution in their retirement plans and has a 96% participation rate, Gannon said. That meant the new offering wasn't a big budget item for the company but could provide support to some employees in need. Similarly, offering a matching contribution seemed like 'an easy win' for The Walt Disney Co. and its workers, said Marianne Lynch, a senior manager of executive benefits and hypercare for the company. 'It's a huge, huge benefit to reduce that burden' of student loan debt, Lynch said. At Disney, 97% of employees already receive the full 401(k) match, but for those who don't, it's a way not to miss out on the matching funds to which they're already entitled, she added. 'The only change here is you're giving them another way to earn that match by paying their student debt,' Rinko said. At companies where most employees already receive the full matching contribution, some leaders may ask, 'Why bother?' with a student loan repayment match, Rinko said. 'The reason is, if it's just 1% or 2%, if you can find a path for that small number, for those people who are usually in the greatest need to earn the match, why not?' Rinko said.
